Fatal interstitial lung disease associated with a series of tyrosine kinase inhibitors treatment in a non-small cell lung cancer patient: a case report

Tyrosine kinase inhibitors have significantly improved outcomes for non-small cell lung cancer patient. However, notwithstanding the favorable clinical effects, preclinical toxicity and clinical adverse effects (AEs) inevitably appeared. The impact on safety and degree of toxicity of these promising...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ting, Hu, Jiong, Shi, Yongheng, Wang, Liwei, Jiao, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798260/
https://www.ncbi.nlm.nih.gov/pubmed/35117740
http://dx.doi.org/10.21037/tcr.2020.03.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798260/
https://www.ncbi.nlm.nih.gov/pubmed/35117740
http://dx.doi.org/10.21037/tcr.2020.03.76

Ejemplares similares